IP Library › Granted Patent US 12,252,398
Granted Patent B2
US 12,252,398 · App. 18/515,193 · Granted Mar 18, 2025

Nitric oxide releasing compositions

Inventors: Gilly Regev (Vancouver, CA); Christopher C. Miller (North Vancouver, CA)
Assignee: SaNOtize Research and Development Corp.
C01B21/24A61K47/02A61K47/12C01P2006/12C01P2006/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,252,398
App. No.
18/515,193
Granted
Mar 18, 2025
Kind
B2
Abstract

Nitric oxide (NO) generating compositions can include a nitrite component, an acidifying component, and a support material configured to carry one of the nitrite component and the acidifying agent. In some examples, the support material can minimize NO generation prior to addition of an activating amount of a suitable solvent.

Claims (15)

1. A particulate composition, comprising:

a blend of a nitrite component in a dry particulate form and an acidifying agent in a dry particulate form, wherein one, but not both, of the nitrite component and the acidifying agent is carried by a support material.

2. The particulate composition of claim 1 , wherein the nitrite component comprises sodium nitrite, potassium nitrite, barium nitrite, calcium nitrite, nitrite orotate, amyl nitrite, magnesium nitrite, or a combination thereof.

3. The particulate composition of claim 1 , wherein the acidifying agent comprises ascorbic acid, ascorbyl palmitate, salicylic acid, malic acid, lactic acid, citric acid, formic acid, benzoic acid, tartaric acid, hydrochloric acid, sulfuric acid, phosphoric acid, or a combination thereof.

4. The particulate composition of claim 1 , wherein the support material comprises carbon black, activated carbon, a metal oxide, a silica, a silicate, a metal phosphate, or a combination thereof.

5. The particulate composition of claim 1 , wherein the support material has a surface area of at least 0.1 meters squared per gram (m 2 /g).

6. The particulate composition of claim 1 , wherein the support material has a pore volume of at least 0.01 cubic centimeters per gram (cc/g).

7. The particulate composition of claim 1 , wherein the support material is a calcined support material.

8. The particulate composition of claim 1 , wherein the nitrite component and the acidifying agent are present in the particulate composition at a weight ratio of from about 1:2 to about 2:1.

9. The particulate composition of claim 1 , wherein the support material is present in the particulate composition at a weight ratio of from about 0.05:1 to about 10:1 with the nitrite component or the acidifying agent.

10. The particulate composition of claim 1 , wherein the nitrite component is present in the particulate composition in an amount of from about 0.05 wt % to about 99.5 wt %.

11. The particulate composition of claim 1 , wherein the acidifying agent is present in the particulate composition in an amount of from about 0.05 wt % to about 99.5 wt %.

12. The particulate composition of claim 1 , wherein the support material is present in the particulate composition in an amount of from about 0.05 wt % to about 99.5 wt %.

13. The particulate composition of claim 1 , wherein the nitrite component is carried by the support material.

14. The particulate composition of claim 1 , wherein the acidifying agent is carried by the support material.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2024
From: REGEV, GILLY; MILLER, CHRISTOPHER C.
To: SANOTIZE RESEARCH AND DEVELOPMENT CORP.
Reel/Frame 068816/0722 →
Continuity (4)
Division 17967717 · Oct 17, 2022
Continuation 16352741 · Mar 13, 2019
Provisional Application 62642536 · Mar 13, 2018
Related Publication 20240158232A1 · May 16, 2024
References Cited (56)
US 6605304B1 · Wellinghoff · 2003 [cited by examiner]
US 6709681B2 · Benjamin et al. · 2004 [cited by applicant]
US 7040313B2 · Fine et al. · 2006 [cited by applicant]
US 7048951B1 · Seitz et al. · 2006 [cited by applicant]
US 8980331B2 · Chen et al. · 2015 [cited by applicant]
US 9445996B2 · Chen et al. · 2016 [cited by applicant]
US 10537697B2 · Montgomery et al. · 2020 [cited by applicant]
US 10543336B2 · Miller et al. · 2020 [cited by applicant]
US 10758703B2 · Kohlmann et al. · 2020 [cited by applicant]
US 10751364B2 · Miller et al. · 2020 [cited by applicant]
US 11304972B2 · Miller et al. · 2022 [cited by applicant]
US 11472705B2 · Regev · 2022 [cited by examiner]
US 11820652B2 · Regev · 2023 [cited by examiner]
US 20050036949A1 · Tucker et al. · 2005 [cited by applicant]
US 20050037093A1 · Benjamin · 2005 [cited by applicant]
US 20060008529A1 · Meyerhoff et al. · 2006 [cited by applicant]
US 20070116785A1 · Miller · 2007 [cited by applicant]
US 20090196930A1 · Surber et al. · 2009 [cited by applicant]
US 20100040703A1 · Miller et al. · 2010 [cited by applicant]
US 20100262095A1 · Hall · 2010 [cited by applicant]
US 20120003293A1 · Miller et al. · 2012 [cited by applicant]
US 20130330244A1 · Balaban et al. · 2013 [cited by applicant]
US 20140056963A1 · Chen · 2014 [cited by examiner]
US 20150030702A1 · Jezek · 2015 [cited by examiner]
US 20150157657A1 · Stenzler et al. · 2015 [cited by applicant]
US 20210038838A1 · Acker et al. · 2021 [cited by applicant]
US 20210145732A1 · Minton et al. · 2021 [cited by applicant]
US 20220040224A1 · Miller et al. · 2022 [cited by applicant]
US 20220088342A1 · Fine · 2022 [cited by applicant]
US 20220160792A1 · Bryan · 2022 [cited by applicant]
CA 2930189A1 · 2015 [cited by applicant]
CA 2946828A1 · 2015 [cited by applicant]
CA 2706828C · 2016 [cited by applicant]
WO WO9939574A2 · 1999 [cited by applicant]
WO WO03013489A1 · 2003 [cited by applicant]
WO WO03020211A2 · 2003 [cited by applicant]
WO WO2009019498A2 · 2009 [cited by applicant]
WO WO2009086470A2 · 2009 [cited by applicant]
WO WO2009097343A1 · 2009 [cited by applicant]
WO WO2009131931A1 · 2009 [cited by applicant]
WO WO2011085484A1 · 2011 [cited by applicant]
WO WO2013063354A1 · 2013 [cited by applicant]
WO WO2015058127A1 · 2015 [cited by applicant]
WO WO2015138406A1 · 2015 [cited by applicant]
WO WO2018049291 · 2018 [cited by applicant]
Adam et al.; “A Clinical Trial of Hypertonic Saline Nasal Spray in Subjects with the Common Cold or Rhinosinusitis;” Archives of Family Medicine; (Jan.-Feb. 1998); pp. 39-43; vol. 7, No. 1. [cited by applicant]
Gregg et al.; “Functionalised Solids Delivering Bioactive Nitric Oxide Gas for Therapeutic Applications;” Materials Today Communications; (2017); pp. 95-105; vol. 12; <doi: 10.1016/j.mtcomm.2017.07.007>. [cited by applicant]
International Search Report issued Sep. 11, 2019, in International Application No. PCT/IB2019/000472, filed Mar. 13, 2019; 7 pages. [cited by applicant]
Meinert et al.; “Clinical Trials: Design, Conduct, and Analysis;” Monographs in Epidemiology and Biostatistics; (1986); 11 pages; vol. 8; [Contents]. [cited by applicant]
Regev-Shoshani et al.: “Prophylactic Nitric Oxide Treatment Reduces Incidence of Bovine Respiratory Disease Complex in Beef Cattle Arriving at a Feedlot;” Research in Veterinary Science; (Oct. 2014); pp. 606-611; vol. 9… [cited by applicant]
Regev-Shoshani et al.; “A Nitric Oxide-Releasing Solution as a Potential Treatment for Fungi Associated with Tinea Pedis;” Journal of Applied Microbiology; (Feb. 2013); pp. 536-544; vol. 114, No. 2. [cited by applicant]
Regev-Shoshani et al.; “Safety, Bioavailability and Mechanism of Action of Nitric Oxide to Control Bovine Respiratory Disease Complex in Calves Entering a Feetlot;” Research in Veterinary Science; (Apr. 2014); pp. 328-3… [cited by applicant]
Schairer et al.; “The Potential of Nitric Oxide Releasing Therapies as Antimicrobial Agents;” Virulence; (May/Jun. 2012); pp. 271-279; vol. 3, No. 3; <doi: 10.4161/viru.20328 >. [cited by applicant]
Seabra et al.; “Nictric Oxide-Releasing Vehicles for Biomedical Applications;” Journal of Materials Chemistry; (2010); pp. 1624-1637; vol. 20; <doi: 10.1039/b912493b>. [cited by applicant]
Taylor et al.; “Early Results Using a Dynamic Method for Delayed Primary Closure of Fasciotomy Wounds;” Journal of American College of Surgeons; (Nov. 2003); pp. 872-878; vol. 197, No. 5. [cited by applicant]
Weller et al.; “The Effects of Topical Treatment with Acidified Nitrite on Wound Healing in Normal and Diabetic Mice;” Nitric Oxide; (Apr. 27, 2006); pp. 395-399; vol. 15, No. 4; <doi: 10.1016/j.niox.2006.04.002 >. [cited by applicant]